ARTICLES BY ABBY PROCH
-
Why Radioligand Therapy Studies Look Nothing Like Standard Oncology Phase 1s11/12/2026
Radioligand therapy (RLT) trials demand specialization. Affibody's Fredrik Frejd explains how they differ in design and execution from standard oncology Phase 1 studies.
-
Years Before Clinical Trials: The Decisions That Shape The Future Of Academic Cancer Discoveries11/11/2026
David Adler, MD, Ph.D., MBA, explains how earlier collaboration between academic and pharma researchers can strengthen oncology discoveries that lead to clinical trials.
-
Two Parallel Trials, A Potential New Option For Protection From COVID-1911/10/2026
Invivyd’s Michael Mina, MD, Ph.D., discusses LIBERTY and DECLARATION, exploring how monoclonal antibodies could expand COVID-19 protection alongside vaccines.
-
Lupus Researchers Now Have A Three-Pillar RWD Platform To Support Discovery And Development11/6/2026
Lupus Nexus unites a registry, biorepository, and data exchange to give researchers longitudinal real-world data without building the infrastructure from scratch.
-
As U.S. Trial Share Slips, A Coalition Maps A Path To Broader Patient Access11/6/2026
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
-
Novel Science, Familiar Regulatory Pathways: Inside Tonix's Clinical Development Strategy11/6/2026
Tonix CEO Seth Lederman, MD, explains how the company pairs novel science with proven regulatory paths across fibromyalgia, depression, and Lyme disease.
-
A Window Into Aging: Why Skin Is the First Test For RLS-149611/5/2026
Rubedo’s Marco Quarta explains how patient selection, controls, biopsies, and biomarkers shaped early RLS-1496 trial protocols.
-
Brazil's Regulatory Transformation: Building And Supporting Sites Beyond The AMCs11/4/2026
Our expert chat about Brazil’s clinical research transformation concludes with SBOC President-elect Fabio Franke, who explores building sustainable trial capacity beyond the country’s major AMCs.
-
Brazil's Regulatory Transformation: Expanding Clinical Trial Participation11/3/2026
A discussion of Brazil’s clinical research transformation continues as this Q&A series turns to Maiko L. Tonini, Ph.D., of Brazil’s Ministry of Health, to explore expanding clinical trial participation.
-
Brazil's Regulatory Transformation: A New Era For Clinical Development11/2/2026
Brazil’s clinical research transformation takes center stage as this new Q&A series opens with Interfarma CEO and former ANVISA director Renato Porto.
-
Ossium's Unconventional Site Strategy For Studying A Novel Bone Marrow Donor Source10/23/2026
Ossium CEO Kevin Caldwell explains how an unconventional multisite Phase 1 trial is shaping the company's novel bone marrow product’s path ahead.
-
Calidi's Study Aims To Have An Oncolytic Virus Outsmart The Immune System10/2/2026
Calidi’s Eric Poma, Ph.D., explains how CLD-401 could evade immune clearance — and how the biotech is designing Phase 1 to prove safety and efficacy fast.
-
New Imaging Approach Could Improve IPF Trial Design10/1/2026
AI-powered quantitative CT could help sponsors detect treatment effects earlier, strengthen IPF trial endpoints, and make better go/no-go decisions.
-
Examining The Potential Of P-tau217 To Provide Earlier Diagnosis Of Alzheimer's9/25/2026
P-tau217 blood tests could accelerate Alzheimer’s diagnosis. Lilly’s Nino Sireci, MD, MSc, explains the research, evidence thus far, potential clinical use, and next steps.
-
How VNS-REHAB Aims To Improve Stroke Recovery After Patients Have Plateaued9/22/2026
Learn how a stroke trial standardized intensive therapy, sustained patient adherence, and exposed access barriers after FDA approval.
-
Repurposing Three FDA-Approved Drugs For A New Stroke Recovery Strategy9/17/2026
When three drugs become one — the polypharmacology strategy, 505(b)(2) pathway, and objective endpoints Nuero-Innovators is relying on to bring new hope to stroke patients.
-
Coalition Takes Guesswork Out Of Charcot-Marie-Tooth Disease Research With New Guidance9/16/2026
A new Charcot-Marie-Tooth guidance introduces practical recommendations to help sponsors design clearer, more patient-centered, regulator-ready trials.
-
Dose Escalation, Combination Strategy Keep Aprea Ahead In Its Oncology Trials9/2/2026
Aprea’s Gene Kennedy explains how smart dose escalation, next-gen sequencing, and combination planning are helping the company advance its oncology trial for multiple solid tumor types.
-
How A $96M Gift Is Transforming Pediatric Brain Cancer Clinical Trial Infrastructure9/1/2026
By pairing donor priorities with research needs at Children's National, Milken Institute SPARC is turning philanthropy into faster trials, stronger infrastructure, and long-term care goals.
-
Planning A Global Clinical Trial With The Right Sites, Not The Most Sites8/27/2026
Less is more for Yi Larson and the team at Excursion Therapeutics, which opted to build right site network — not the largest one — for its Phase 2 trial.
-
Turning A Historically Limited Modality Into A Respiratory Drug Opportunity8/26/2026
How can sponsors revive a promising modality with known safety limits? Vast Therapeutics CEO Nate Stasko, Ph.D., explains how ALX1 is reshaping nitric oxide delivery.
-
Immune Priming, Oncolytic Viruses, And The Next Phase Of Solid Tumor Immunotherapy8/25/2026
Can priming with oncolytic viruses be a better path to reeducating the immune system to recognize and attack cancer? Oncolytics Biotech advisor Richard Vile, Ph.D., says yes.
-
What BriaCell's Trial Design Says About Real-World Cancer Research8/24/2026
BriaCell President and CEO William Williams, MD, shares how broader eligibility criteria and physician’s choice controls can better reflect real-world cancer care.
-
'How Do You Feel?': Designing A Cardiac Trial With A Patient-Reported Primary Endpoint8/21/2026
Imbria Pharmaceuticals' Albert Kim, MD, Ph.D., shares why PROs are the point of the company's FORTITUDE-HCM trial for patients with non-obstructive hypertrophic cardiomyopathy.
-
Stock Options: Choosing The Right Viral Inoculum For An Early-Phase Norovirus Trial8/20/2026
Viral stock can make or break a norovirus challenge study. Cocrystal Pharma's Sam Lee explains why inoculum quality, infectivity, and availability matter.
-
Rare Disease Study Gets A Boost From Crowdsourced Patient Reported Data8/18/2026
Jen A. Levitt, MD, explains how crowdsourced patient-reported data and AI tools can compress rare disease research timelines and surface new signals.
-
The Patient Advocacy Strategy Behind Skyhawk's Rapid Enrollment8/13/2026
Skyhawk’s patient-first approach shows how advocacy partnerships, site engagement, and operational quality can accelerate enrollment without losing focus on patients.
-
What The FDA's Latest Move On Psychedelics Means For Non-Hallucinogenic Drug Sponsors8/13/2026
Taking another angle to the FDA focus on psychedelic research, Enveric Biosciences CEO Joseph Tucker, Ph.D., explores what the FDA’s moves mean for non-hallucinogenic drug sponsors.
-
What The FDA's Psychedelic Drug Focus Means For Classic Psychedelic Development8/13/2026
Complementing an interview with Enveric Bioscience's Joseph Tucker, Ph.D., this Q&A explores Josh Hardman's thoughts on what FDA’s psychedelic focus could mean for classic psychedelic development.
-
How FDA Alignment Is Shaping Opus Genetics' OPGx-LCA5 Development Strategy8/12/2026
Opus Genetics shares how FDA alignment yielded a clearer path for its ultra-rare LCA5 gene therapy, shaping trial design, evidence generation, and operations.
-
What It Takes To Validate A Biomarker For Real-World, Post-Transplant Care8/7/2026
Yelena Bushman, MBA, VP of cell therapy and transplant at CareDx, discusses the operational challenges of validating biomarkers for post-transplant care.
-
C-Suite Changes Help Biotech Narrow Focus But Maintain Drive To Treat Fatal Neonatal Brain Injury8/5/2026
Newly-appointed leaders at ReAlta Life Sciences discuss their skill sets, their goals for advancing a therapy for hypoxic ischemic encephalopathy (HIE), and how they keep momentum as they strive to help bring this potentially lifesaving therapy to market.
-
From Signal To Strategy: What Oncology Basket Trials Can Teach Clinical Development Teams7/29/2026
AbbVie's Svetlana Kobina discusses how basket trials can help clinical development teams move from early clinical signals to a more disciplined strategy.
-
ImvivaBio's Trial For Off-The-Shelf CAR-T Strategy For Aggressive Malignancies7/28/2026
ImvivaBio CMO Jan Davidson-Moncada, MD, Ph.D., discusses the company's Phase 1b/2 study for aggressive T-cell malignancies, explaining their unmet need, the rationale for an allogeneic approach, and how they plan to address immune rejection.
-
Expanded Access And Rollover Design Help CytoDyn Reach High-Need Cancer Patients7/24/2026
CEO Jay Lalezari and CFO Robert E. Hoffman share how CytoDyn meet patient needs when they approach trial design for cancer trials.
-
Unlocking Gentler, Cost-Efficient TIL Therapy For Cold Tumors7/20/2026
CuraCell Head of Clinical Operations Torbjörn Ström discusses, in the context of CC-38 and CytoPLY-derived tumor-infiltrating lymphocytes (TILs), the utility of named-patient experience, dosing and preconditioning, and T-cell therapy capabilities in cold solid tumors.
-
What Pistoia Alliance's AI Poll Reveals About Industry Readiness And Regulatory Confidence7/17/2026
Pistoia Alliance President Becky Upton, Ph.D., reviews findings from a poll about AI use in clinical research conducted at Clinical Trials Technology Congress (CTTC) that revealed barriers to adoption, early ROI, emerging use cases, and the role of patient-generated data.
-
The Promise Of Bispecifics In The Quest For Outpatient Immunotherapy7/15/2026
START San Antonio's Drew Rasco, MD, reflects on the evolution of immunotherapy and highlights how novel therapies such as bispecifics are both challenging and intriguing for principal investigators (PIs).
-
Digital Twins Enhance Disease Progression Measurements In FSHD7/14/2026
Digital twins can transform trial design by making data more robust and alleviating patient burden. In this interview, Epicrispr CEO Amber Salzman, Ph.D., shares how the company's using it to reliably predict muscle volume change in their trial for a FSHD gene therapy.
-
Navigating The New EU Pharmaceutical Legislation: Key Implications For Pediatric Drug Development7/13/2026
UCB’s Senior Development Strategy Lead Pediatrics Martine Dehlinger-Kremer, Ph.D., discusses updates to the new EU Pharma legislation and how they impact pediatric drug development, including earlier pediatric investigational plans .
-
i-Cubed Used End-To-End AI In A Proof-Of-Concept Trial. Here's What They Learned7/2/2026
Discover how well AI fared in document generation, patient engagement, data integration, and more in an end-to-end proof-of-concept study run by i-Cubed.
-
Social Media Is Replete With Patient RWD, But How Can Researchers Best Use It?7/1/2026
Pistoia Alliance's Thierry Escudier and Aditya Tyagi discuss how social media listening is used in clinical research, how it supports established evidence-generation methods, and how it can become a credible, structured input for drug development.
-
Helus Shares Experience Studying Adjunctive Psychedelic For Major Depressive Disorder6/26/2026
Helus Pharma CMO Amir Inamdar discusses the strategic rationale behind its Phase 3 trial for major depressive disorder, including its adjunctive-treatment approach, patient population selection, and endpoint strategy.
-
RWE Increasingly Supports Rare Disease Research As RCTs Alone Fall Short6/25/2026
Chiesi's Rachele Berria, MD, Ph.D., discusses how RWE is reshaping rare disease drug development strategies, from leveraging registries and patient-reported outcomes to navigating evolving regulatory expectations.
-
Designing Trials For Disease Modification: Cereno Scientific's Approach To Pulmonary Arterial Hypertension6/10/2026
Cereno Scientific’s Rahul Agrawal discusses the scientific and strategic rationale behind extending the company’s Phase 2b study duration and how the company incorporated regulator and patient input.
-
New Primary Endpoint For Tetraplegia Drug Gets Support From Patients And The FDA6/9/2026
NervGen CEO Adam Rogers discussed why choosing a hand function endpoint for tetraplegia made sense for patients and how regulators helped guide and support the company's decision.
-
Expanding Access To Cell Therapy Trials Beyond AMCs And Into The Community6/1/2026
CEO Paul J. Hastings discusses Nkarta's decision to bring outpatient dosing into the community setting, including how it communicated with the FDA on safety and how the changes will improve patient access.
-
What's The Role Of HEOR For A Clinical Researcher? A Perspective From ISPOR 20266/1/2026
On the heels of ISPOR 2026, discover what relevancy HEOR has in the world of clinical operations.
-
Safety Is The Mantra In Kivu Bioscience's ADC Trials For Solid Tumors5/29/2026
Kivu Bioscience CEO Mohit Trikha, Ph.D., contends that safer ADCs enable higher effective dosing and could elicit a better response in solid tumors. In this Q&A, he also discusses how parallel trial execution, global site strategy, and stakeholder collaboration support rapid, data-driven development.
-
Taking On Patient Recruitment From Another Angle — The Payer5/28/2026
Medzown CEO Jennifer Carter, MD, discusses the challenge of patient recruitment and how coalescing around clinical care data might be a better “in” for recruitment.